© 2005 Oxford University Press
ARTICLE |
Sequence Variants in Toll-Like Receptor Gene Cluster (TLR6-TLR1-TLR10) and Prostate Cancer Risk
Affiliations of authors: Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC (JS, SLZ, BC, LL, GL, WL, AT, ART, DAM, JX); Department of Radiation Sciences and Oncology, University of Umeå, Umeå, Sweden (FW, HG); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (KB, H-OA); Department of Urology and Clinical Medicine, Örebro University Hospital, Örebro, Sweden, and Regional Oncological Center, University Hospital, Uppsala, Sweden (J-EJ); Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD (WBI)
Correspondence to: Jianfeng Xu, Dr PH, MD, Center for Human Genomics, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157 (e-mail: jxu{at}wfubmc.edu).
Background: Chronic inflammation plays an important role in several human cancers and may be involved in the etiology of prostate cancer. Toll-like receptors (TLRs) are important in the innate immune response to pathogens and in cross-talk between innate immunity and adaptive immunity. Our previous finding of an association of TLR4 gene sequence variants and prostate cancer risk provides evidence for a role of TLRs in prostate cancer. In this study, we investigated whether sequence variants in the TLR6-TLR1-TLR10 gene cluster, residing within a 54-kb region on 4p14, were associated with prostate cancer risk. Methods: We selected 32 single-nucleotide polymorphisms (SNPs) covering these three genes and genotyped these SNPs in 96 control subjects from the Cancer Prostate in Sweden (CAPS) population-based prostate cancer case–control study. Five distinct haplotype blocks were inferred at this region, and we identified 17 haplotype-tagging SNPs (htSNPs) that could uniquely describe >95% of the haplotypes. These 17 htSNPs were then genotyped in the entire CAPS study population (1383 case subjects and 780 control subjects). Odds ratios of prostate cancer for the carriers of a variant allele versus those with the wild-type allele were estimated using unconditional logistic regression. Results: The allele frequencies of 11 of the 17 SNPs were statistically significantly different between case and control subjects (P = .04–.001), with odds ratios for variant allele carriers (homozygous or heterozygous) compared with wild-type allele carriers ranging from 1.20 (95% confidence interval [CI] = 1.00 to 1.43) to 1.38 (95% CI = 1.12 to 1.70). Phylogenetic tree analyses of common haplotypes identified a clade of two evolutionarily related haplotypes that are statistically significantly associated with prostate cancer risk. These two haplotypes contain all the risk alleles of these 11 associated SNPs. Conclusion: The observed multiple associated SNPs at the TLR6-TLR1-TLR10 gene cluster were dependent and suggest the presence of a founder prostate cancer risk variant on this haplotype background. The TLR6-TLR1-TLR10 gene cluster may play a role in prostate cancer risk, although further functional studies are needed to pinpoint the disease-associated variants in this gene cluster.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. R. Stark, F. Wiklund, H. Gronberg, F. Schumacher, J. A. Sinnott, M. J. Stampfer, L. A. Mucci, and P. Kraft Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1859 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Purdue, Q. Lan, S. S. Wang, A. Kricker, I. Menashe, T.-Z. Zheng, P. Hartge, A. E. Grulich, Y. Zhang, L. M. Morton, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma Carcinogenesis, February 1, 2009; 30(2): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Lange, J. Sun, L. A. Lange, S. L. Zheng, D. Duggan, J. D. Carpten, H. Gronberg, W. B. Isaacs, J. Xu, and B.-L. Chang Family-Based Samples Can Play an Important Role in Genetic Association Studies Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2208 - 2214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Paone, D. Starace, R. Galli, F. Padula, P. De Cesaris, A. Filippini, E. Ziparo, and A. Riccioli Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-{alpha}-dependent mechanism Carcinogenesis, July 1, 2008; 29(7): 1334 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Chen, E. Giovannucci, P. Kraft, R. Lazarus, and D. J. Hunter Association between Toll-Like Receptor Gene Cluster (TLR6, TLR1, and TLR10) and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1982 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, F. R. Schumacher, S. J. Plummer, E. Jorgenson, G. Casey, and J. S. Witte trans-Fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant Carcinogenesis, June 1, 2007; 28(6): 1232 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-F. Wang Control of Regulatory T Cells and Cancer Immunity by Toll-Like Receptors Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 177 - 182. [Full Text] [PDF]
|
|
|
|
|
|
I. Cheng, S. J. Plummer, G. Casey, and J. S. Witte Toll-Like Receptor 4 Genetic Variation and Advanced Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 352 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. McKay, R. Kaaks, M. Johansson, C. Biessy, F. Wiklund, K. Balter, H.-O. Adami, C. Boillot, L. Gioia-Patricola, F. Canzian, et al. Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 169 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sun, Y. Gao, W. Tan, S. Ma, X. Zhang, Y. Wang, Q. Zhang, Y. Guo, D. Zhao, C. Zeng, et al. Haplotypes in Matrix Metalloproteinase Gene Cluster on Chromosome 11q22 Contribute to the Risk of Lung Cancer Development and Progression Clin. Cancer Res., December 1, 2006; 12(23): 7009 - 7017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-X. Zhou, W.-H. Jia, G.-P. Shen, H.-d. Qin, X.-J. Yu, L.-Z. Chen, Q.-S. Feng, Y. Y. Shugart, and Y.-X. Zeng Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 862 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sun, F. Wiklund, F.-C. Hsu, K. Balter, S. L. Zheng, J.-E. Johansson, B. Chang, W. Liu, T. Li, A. R. Turner, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 480 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Chen, E. Giovannucci, R. Lazarus, P. Kraft, S. Ketkar, and D. J. Hunter Sequence Variants of Toll-Like Receptor 4 and Susceptibility to Prostate Cancer Cancer Res., December 15, 2005; 65(24): 11771 - 11778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, J. Lowey, F. Wiklund, J. Sun, F. Lindmark, F.-C. Hsu, L. Dimitrov, B. Chang, A. R. Turner, W. Liu, et al. The Interaction of Four Genes in the Inflammation Pathway Significantly Predicts Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2563 - 2568. [Abstract] [Full Text] [PDF]
|
|